Efficacy of COVID-19 vaccines by race and ethnicity
- 5 May 2022
- journal article
- research article
- Published by Elsevier in Public Health
- Vol. 208, 14-17
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsNew England Journal of Medicine, 2020
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19New England Journal of Medicine, 2020
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineNew England Journal of Medicine, 2020
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- COVID-19 and ethnicity: who will research results apply to?The Lancet, 2020
- The impact of ethnicity on clinical outcomes in COVID-19: A systematic revieweClinicalMedicine, 2020
- Ethnic minority under‐representation in clinical trialsJournal of Health Organization and Management, 2003